Latest News and Press Releases

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to...

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...

Pune, Oct. 03, 2023 (GLOBE NEWSWIRE) -- “The SNS Insider report states that the Recombinant Vaccines Market reached USD 9.18 billion in 2022 and is projected to attain USD 21.46 billion by 2030,...

New York, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Global Shingles Vaccine Market was valued at US$ 3.5 Bn in 2021 and is expected to reach US$ 14.1 Bn by 2032 finds Persistence Market Research in a recent...